SYNGENE.BO
Last
- - (-%)Time
-Previous Close
-
Open
-High
-Low
-
Latest News
Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda
published on April 21, 2026, 10:39 am (via GlobeNewswire)
Related Stocks
Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.